Cargando…

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma

Pembrolizumab has been available for the treatment of radical resectable urothelial carcinoma (UC) when it is exacerbated after chemotherapy since December 2017 in Japan. However, the efficacy of chemotherapy for cases progressing after pembrolizumab is unclear. The present study compared the outcom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furubayashi, Nobuki, Hori, Yoshifumi, Morokuma, Futoshi, Tomoda, Toshihisa, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Kuroiwa, Kentaro, Tokuda, Noriaki, Nakamura, Motonobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976390/ https://www.ncbi.nlm.nih.gov/pubmed/33767860 http://dx.doi.org/10.3892/mco.2021.2253

Ejemplares similares

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Clinical outcome of transperitoneal ureterocutaneostomy using the transverse mesocolon
por: FURUBAYASHI, NOBUKI, et al.
Publicado: (2013)

Change of genitourinary cancer patients’ perception and expectations over the course of pharmacotherapy
por: Satou, Yoshiaki, et al.
Publicado: (2022)

Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomy
por: FURUBAYASHI, NOBUKI, et al.
Publicado: (2014)

Efficacy and safety of third- and fourth-line targeted therapy in Japanese patients with metastatic renal cell carcinoma: A retrospective analysis
por: Takahito, Negishi, et al.
Publicado: (2018)

Biochemical failure after radical prostatectomy in intermediate-risk group men increases with the number of risk factors
por: Furubayashi, Nobuki, et al.
Publicado: (2017)

Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma
por: Negishi, Takahito, et al.
Publicado: (2020)

Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
por: Takamatsu, Dai, et al.
Publicado: (2019)

A Case of Cystic Retroperitoneal Dedifferentiated Liposarcoma Diagnosed by Percutaneous Image-Guided Biopsy
por: Morihara, Kaede, et al.
Publicado: (2023)

Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).
por: Peckham, M. J., et al.
Publicado: (1985)

Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy
por: Williams, Laura, et al.
Publicado: (2009)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report
por: Kamada, Teppei, et al.
Publicado: (2020)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival
por: Nakamori, Keita, et al.
Publicado: (2022)

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
por: Uchida, Hideaki, et al.
Publicado: (2023)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
por: Gu, Yangchun, et al.
Publicado: (2021)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy
por: Huang, Hui-Shan, et al.
Publicado: (2018)

Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report
por: Kondo, Masahiro, et al.
Publicado: (2018)

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Patel, Shetal A., et al.
Publicado: (2021)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v7br7tdg9odo9f1d28ibpvjs6n